Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Jolanda Paolini"'
Autor:
Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100406- (2022)
Introduction: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present
Externí odkaz:
https://doaj.org/article/7369e36175e44454b80a3ac673b3634f
Autor:
D.R. Camidge, Stephanie Green, Jolanda Paolini, Keith D. Wilner, Marileila Varella-Garcia, Steffan N. Ho, Fiona H Blackhall, Silvana Lanzalone, Yi-Long Wu, K. Pestova, Benjamin Solomon, Alice T. Shaw, Anna Polli, J-C. Soria, Tony Mok, Anthony J. Iafrate
Publikováno v:
Annals of Oncology. 29:1964-1971
Background In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship between the percentage of ALK-positive cells by fluorescence in situ h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95578ff2379ab71be2f8aa29d1ba0cc
https://doi.org/10.1093/annonc/mdy242
https://doi.org/10.1093/annonc/mdy242
Autor:
Tiziana Usari, Yiyun Tang, Fiona H Blackhall, Jolanda Paolini, Kazuhiko Nakagawa, Tony Mok, Federico Cappuzzo, Tarek Mekhail, Yi-Long Wu, Benjamin Solomon, Enriqueta Felip, Dong Wan Kim, Keith D. Wilner
Publikováno v:
Journal of Clinical Oncology. 36:2251-2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) –positive advanced nonsquamous non–small-cell lung cancer. Here, we report the final overall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95203cf2561eed4d6192bbc009a3c3e9
https://doi.org/10.1200/jco.2017.77.4794
https://doi.org/10.1200/jco.2017.77.4794
Autor:
Anna Polli, Alice T. Shaw, Kazuhiko Nakagawa, Tony Mok, Benjamin Solomon, Yi-Long Wu, Satoshi Hashigaki, Dong Wan Kim, Keith D. Wilner, Jolanda Paolini, Makoto Nishio, Emiko Ohki, Tiziana Usari
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0ab9bc782e8fc5c6c64ffb4896d1733
https://doi.org/10.4143/crt.2017.280
https://doi.org/10.4143/crt.2017.280
Autor:
Takashi Seto, W. Su, Keith D. Wilner, Tiziana Usari, Noboru Yamamoto, Shun Lu, Y-L. Wu, James Chih-Hsin Yang, Jianying Zhou, D. Kim, Jolanda Paolini, Myung-Ju Ahn, Koichi Goto
Publikováno v:
Journal of Thoracic Oncology. 16:S1087
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::538ad01cff9c2d69b2060a6de753350b
https://doi.org/10.1016/j.jtho.2021.08.474
https://doi.org/10.1016/j.jtho.2021.08.474
Autor:
Yuankai Shi, Matthew H. Taylor, Sergey Orlov, Li Zhang, Keizo Horibe, Fadi Braiteh, Paulina Selaru, William Jeffrey Edenfield, Tae Min Kim, Jin Seok Ahn, Shang Ju Wu, Brian A. Van Tine, Kenji Tamura, Hui-Qiang Huang, Carlo Gambacorti-Passerini, Jolanda Paolini, Taito Esaki, Joseph Thaddeus Beck
Publikováno v:
American Journal of Hematology
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK‐positive or ROS1‐positive advanced non‐small‐cell lung cancer (NSCLC). However, ALK rearrangements are also implicated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ff8f6d43296f0d3cf5505feea7c337
http://hdl.handle.net/10281/186038
http://hdl.handle.net/10281/186038
Autor:
Matthew R. Smith, Mariajose Lechuga, Stephen Clarke, Janette L. Vardy, Isan Chen, Guru Sonpavde, Arnoud J. Templeton, M. Dror Michaelson, Gregory R. Pond, Jolanda Paolini, Andrew J. Armstrong, Edna Chow-Maneval, Shaw-Ling Wang
Publikováno v:
Clinical Genitourinary Cancer. 12:317-324
We retrospectively evaluated the prognostic impact of neutrophil-lymphocyte ratio (NLR) as a marker for inflammatory and immune state in men with progressive metastatic castration resistant prostate cancer (mCRPC) following docetaxel.The SUN-1120 pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2760ef99a4a92d73c4dbe6180f563c
https://doi.org/10.1016/j.clgc.2014.03.005
https://doi.org/10.1016/j.clgc.2014.03.005
Autor:
Shaw-Ling Wang, Edna Chow-Maneval, Guru Sonpavde, Mariajose Lechuga, Matthew R. Smith, Isan Chen, David James Mooney, Lance Leopold, Jolanda Paolini, Matthew D. Galsky, M. Dror Michaelson, Andrew J. Armstrong, Gregory R. Pond, Brian A. Wood
Publikováno v:
BJU International. 114:E25-E31
Objective To investigate the association of radiographic progression defined by Prostate Cancer Working Group (PCWG)-2 guidelines and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods Two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a85860183ee3ed5b4cf6bc05b55851fe
https://doi.org/10.1111/bju.12589
https://doi.org/10.1111/bju.12589
Autor:
Zhixiao Wang, Kenneth A. Kern, E. Claire Dees, Sherry Li, Stephen D. Myers, Jolanda Paolini, Paul J. Healey, Marla J. Brickman, Dennis L. Citrin, Denise A. Yardley
Publikováno v:
Breast Cancer Research and Treatment. 136:759-767
This multicenter, open-label phase II study was conducted to evaluate sunitinib monotherapy in patients with either metastatic or locoregionally recurrent advanced breast cancer. Patients received sunitinib 37.5 mg on a continuous daily dosing schedu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1dfcd11d4ab81106a30c70657bd4b03
https://doi.org/10.1007/s10549-012-2285-0
https://doi.org/10.1007/s10549-012-2285-0
Autor:
Maria Jose Lechuga, Edna Chow Maneval, Manfred Welslau, A. Kretzschmar, J. Randolph Hecht, Takayuki Yoshino, Jolanda Paolini, Edith P. Mitchell, Xun Lin
Publikováno v:
Cancer Management and Research
J Randolph Hecht,1 Edith P Mitchell,2 Takayuki Yoshino,3 Manfred Welslau,4 Xun Lin,5 Edna Chow Maneval,6 Jolanda Paolini,7 Maria Jose Lechuga,7 Albrecht Kretzschmar8 1David Geffen School of Medicine at UCLA, Santa Monica, CA, 2Kimmel Cancer Center of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::864e571ce707cc407cc1ec5fc7aea6d1
https://www.dovepress.com/5-fluorouracil-leucovorin-and-oxaliplatin-mfolfox6-plus-sunitinib-or-b-peer-reviewed-article-CMAR
https://www.dovepress.com/5-fluorouracil-leucovorin-and-oxaliplatin-mfolfox6-plus-sunitinib-or-b-peer-reviewed-article-CMAR